share_log

Moderna | 3: Initial statement of beneficial ownership of securities-Director Hussain Abbas

Moderna | 3: Initial statement of beneficial ownership of securities-Director Hussain Abbas

Moderna | 3:首次持股声明-董事 Hussain Abbas
美股SEC公告 ·  10/04 08:54
Moomoo AI 已提取核心信息
Moderna, Inc. (NASDAQ: MRNA) has reported a new filing with the United States Securities and Exchange Commission (SEC) on October 2, 2024. The Form 3, known as the Initial Statement of Beneficial Ownership of Securities, was submitted by Abbas Hussain, who is identified as a Director and a 10% Owner of the company. The filing, signed by Brian Sandstrom as Attorney-in-Fact on October 4, 2024, indicates that Hussain does not beneficially own any securities directly or indirectly, including derivative securities such as puts, calls, warrants, options, or convertible securities. This form is a standard requirement for new insiders of a publicly-traded company to report their ownership of the company's stock and is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.
Moderna, Inc. (NASDAQ: MRNA) has reported a new filing with the United States Securities and Exchange Commission (SEC) on October 2, 2024. The Form 3, known as the Initial Statement of Beneficial Ownership of Securities, was submitted by Abbas Hussain, who is identified as a Director and a 10% Owner of the company. The filing, signed by Brian Sandstrom as Attorney-in-Fact on October 4, 2024, indicates that Hussain does not beneficially own any securities directly or indirectly, including derivative securities such as puts, calls, warrants, options, or convertible securities. This form is a standard requirement for new insiders of a publicly-traded company to report their ownership of the company's stock and is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934.
Moderna, Inc.(纳斯达克股票代码:MRNA)于2024年10月2日向美国证券交易委员会(SEC)提交了一份新的备案报告。这份名为3号表格的报告,也称为有价证券的初始受益所有权报告,由阿巴斯·胡赛因提交,被确认为该公司的董事兼10%股东。该备案报告由代理律师布莱恩·桑德斯特罗姆于2024年10月4日签署,显示胡赛因并不直接或间接拥有任何有价证券,包括认股权证、认购权、认股权证、期权或可转换证券。这份表格是对公开交易公司新内部人员进行股权所有权报告的标准要求,根据1934年证券交易法案第16(a)条款提交。
Moderna, Inc.(纳斯达克股票代码:MRNA)于2024年10月2日向美国证券交易委员会(SEC)提交了一份新的备案报告。这份名为3号表格的报告,也称为有价证券的初始受益所有权报告,由阿巴斯·胡赛因提交,被确认为该公司的董事兼10%股东。该备案报告由代理律师布莱恩·桑德斯特罗姆于2024年10月4日签署,显示胡赛因并不直接或间接拥有任何有价证券,包括认股权证、认购权、认股权证、期权或可转换证券。这份表格是对公开交易公司新内部人员进行股权所有权报告的标准要求,根据1934年证券交易法案第16(a)条款提交。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息